Poolbeg Pharma plc operates as a clinical-stage pharmaceutical company, headquartered in London, United Kingdom, with a focus on developing treatments for infectious diseases. Its current product pipeline includes: POLB 001: A p38 MAP Kinase inhibitor being advanced for the treatment of severe influenza. POLB 002: An innovative, first-in-class RNA-based immunotherapy, acquired through a licensing agreement, designed for intranasal administration to combat various respiratory viral infections. POLB 003: An intramuscular vaccine aimed at preventing Melioidosis. Beyond specific drug candidates, Poolbeg Pharma holds licensed access to advanced micro- and nanoencapsulation technology. This technology is being leveraged to develop an oral vaccine delivery platform capable of transporting immune-stimulating antigens to specific areas of the gut. The company also utilizes an artificial intelligence-powered program to aid in drug discovery. Furthermore, Poolbeg Pharma is developing a biomarker platform with the goal of identifying individuals at risk of progressing to severe disease. It also operates a sophisticated, model-derived vaccine discovery platform dedicated to uncovering novel vaccine candidates. The company was incorporated in 2021.
—
Poolbeg Pharma plc operates as a clinical-stage pharmaceutical company, headquartered in London, United Kingdom, with a focus on developing treatments for infectious diseases. Its current product pipeline includes: POLB 001: A p38 MAP Kinase inhibitor being advanced for the treatment of severe influenza. POLB 002: An innovative, first-in-class RNA-based immunotherapy, acquired through a licensing agreement, designed for intranasal administration to combat various respiratory viral infections. POLB 003: An intramuscular vaccine aimed at preventing Melioidosis. Beyond specific drug candidates, Poolbeg Pharma holds licensed access to advanced micro- and nanoencapsulation technology. This technology is being leveraged to develop an oral vaccine delivery platform capable of transporting immune-stimulating antigens to specific areas of the gut. The company also utilizes an artificial intelligence-powered program to aid in drug discovery. Furthermore, Poolbeg Pharma is developing a biomarker platform with the goal of identifying individuals at risk of progressing to severe disease. It also operates a sophisticated, model-derived vaccine discovery platform dedicated to uncovering novel vaccine candidates. The company was incorporated in 2021.
—
Daily adjusted close
Poolbeg Pharma plc operates as a clinical-stage pharmaceutical company, headquartered in London, United Kingdom, with a focus on developing treatments for infectious diseases. Its current product pipeline includes: POLB 001: A p38 MAP Kinase inhibitor being advanced for the treatment of severe influenza. POLB 002: An innovative, first-in-class RNA-based immunotherapy, acquired through a licensing agreement, designed for intranasal administration to combat various respiratory viral infections. POLB 003: An intramuscular vaccine aimed at preventing Melioidosis. Beyond specific drug candidates, Poolbeg Pharma holds licensed access to advanced micro- and nanoencapsulation technology. This technology is being leveraged to develop an oral vaccine delivery platform capable of transporting immune-stimulating antigens to specific areas of the gut. The company also utilizes an artificial intelligence-powered program to aid in drug discovery. Furthermore, Poolbeg Pharma is developing a biomarker platform with the goal of identifying individuals at risk of progressing to severe disease. It also operates a sophisticated, model-derived vaccine discovery platform dedicated to uncovering novel vaccine candidates. The company was incorporated in 2021.